Free Trial
→ Your free book is about to disappear (From Profits Run) (Ad)tc pixel
NASDAQ:PXMD

PaxMedica Q3 2023 Earnings Results & Report

PaxMedica logo
$0.0007 0.00 (0.00%)
As of 11/11/2026 09:30 AM Eastern

PaxMedica reported Q3 2023 earnings on November 15, 2023. The company reported EPS of -$5.20.

Research:Profile

Earnings Announcement Details

Quarter
Q3 2023
Report Date

PaxMedica EPS Results

Actual EPS
-$5.20
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

PaxMedica Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

PaxMedica's next earnings date is estimated for Wednesday, December 2, 2026, based on past reporting schedules.

Conference Call Resources

PaxMedica Q3 2023 Earnings FAQ

PaxMedica (NASDAQ:PXMD) reported earnings of -$5.20 per share for Q3 2023. The report was announced on Wednesday, November 15, 2023.

PaxMedica's next earnings date is estimated for Wednesday, December 2, 2026. MarketBeat tracks confirmed and estimated earnings dates for PaxMedica on the company's earnings history page.

PaxMedica Earnings Headlines

PaxMedica, Inc. (PXMD) - Yahoo Finance
July 11, 2025  |  nz.finance.yahoo.comhttps://nz.finance.yahoo.com/quote/PXMD/
Study Links Iron Deficiency to Disturbed Sleep Among Autism, ADHD Patients
September 23, 2024  |  msn.comhttps://www.msn.com/en-us/health/other/study-links-iron-deficiency-to-disturbed-sleep-among-autism-adhd-patients/ar-AA1r3Lgv
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This past May, flooding cut the supply route into the largest uranium complex on the planet, and in July Cigar Lake went down a second time. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.tc pixel
November 13 at 1:00 AM  |  Digest Publishing (Ad)
BioMedNewsBreaks — PaxMedica Inc. (PXMD) Announces Immediate Exercise of Warrants to Total Approximately $884K
September 3, 2024  |  msn.comhttps://www.msn.com/en-us/health/other/biomednewsbreaks-paxmedica-inc-pxmd-announces-immediate-exercise-of-warrants-to-total-approximately-884k/ar-AA1pVZlL
Yale Study Unravels Autism, Brain Growth Patterns
September 1, 2024  |  msn.comhttps://www.msn.com/en-us/health/other/yale-study-unravels-autism-brain-growth-patterns/ar-AA1pIVO0
PaxMedica, Inc.: PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection
August 27, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-08/63099646-paxmedica-inc-paxmedica-reports-first-patient-treated-with-pax-101-for-fatal-african-sleeping-sickness-infection-200.htm
See More PaxMedica Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PaxMedica? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PaxMedica and other key companies, straight to your email.

About PaxMedica

PaxMedica (NASDAQ:PXMD) is a clinical-stage biopharmaceutical company focused on developing treatments for neurodevelopmental disorders and other conditions with significant unmet medical needs. The company’s research has centered on therapies intended to address symptoms and underlying biological mechanisms associated with these disorders.

PaxMedica’s primary product candidate is PAX-101, an intravenous formulation of suramin, an established antiparasitic compound. The company has evaluated PAX-101 in clinical studies for autism spectrum disorder and has also explored its potential in other neurodevelopmental conditions, including Fragile X syndrome and Phelan-McDermid syndrome.

In addition to its neurodevelopmental research, PaxMedica has pursued opportunities involving suramin in infectious disease, including human African trypanosomiasis, commonly known as sleeping sickness. The company is based in the United States and has focused its development activities on advancing clinical programs rather than marketing commercially approved products. Howard J. Jaffe, M.D., has been associated with the company’s leadership.

View PaxMedica Profile
Earnings Tools